News - Pharmaceutical, Bayer

Filter

Current filters:

PharmaceuticalBayer

Popular Filters

1 to 25 of 293 results

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

Bayer’s Nexavar cleared in Japan for differentiated thyroid cancer

Bayer’s Nexavar cleared in Japan for differentiated thyroid cancer

20-06-2014

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved German pharma major Bayer’s oral…

BayerJapanNexavarOncologyPharmaceuticalRegulation

Bayer files for EMA approval of Eylea for macular edema secondary to BRVO

Bayer files for EMA approval of Eylea for macular edema secondary to BRVO

11-06-2014

German pharma major Bayer has submitted an application to the European Medicines Agency seeking marketing…

BayerEuropeEyleaOphthalmicsPharmaceuticalRegeneronRegulation

Dieter Weinand to become president of Bayer HealthCare

Dieter Weinand to become president of Bayer HealthCare

05-06-2014

Dieter Weinand will become President of the HealthCare division of German pharma major Bayer Pharmaceuticals,…

BayerBoardroomPharmaceuticalUSA

Planned top executive moves at Bayer and Sanofi

04-06-2014

There were a couple of surprise planned departures and relocations revealed at European pharmaceutical…

BayerBoardroomManagementPharmaceuticalSanofi

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201

02-06-2014

Finland-based drugmaker Orion Corp has entered into a global partnership with German pharma major Bayer…

BayerGlobalLicensingODM-201OncologyOrion CorpPharmaceuticalResearch

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

Bayer explores Russian options in the context of Pharma 2020 strategy

Bayer explores Russian options in the context of Pharma 2020 strategy

28-05-2014

Bayer HealthCare, one of the business units of German drug major Bayer, is exploring all options for…

Abbott LaboratoriesBayerGermanyHealthcareManufacturing plantOzonPharmaceuticalPharmaceutical drugPharmacologyPoliticsRussia

Bayer divests interventional device business for $415 million

15-05-2014

German pharma and life sciences major Bayer has entered into a definitive agreement to sell its interventional…

BayerMergers & AcquisitionsPharmaceutical

Bayer to make clinical trial data more accessible to researchers

Bayer to make clinical trial data more accessible to researchers

14-05-2014

German drug major Bayer has joined a host of other pharma companies in announcing that it will start…

BayerBoehringer IngelheimGermanyHealth Medical PharmaPharmaceuticalPharmaceutical industryPharmaceutical sciencesResearchScience

FDA approves new indication for Bayer's Kogenate

12-05-2014

The US Food and Drug Administration has approved a new indication for German drug major Bayer's Kogenate…

BayerHematologyKogenate FSPharmaceuticalRegulationUSA

GPs lack awareness of NICE guidelines on HMB, survey shows

GPs lack awareness of NICE guidelines on HMB, survey shows

09-05-2014

Less than 5% of UK general practitioners (GPs) prescribe in line with guidelines from the National Institute…

BayerHealth Medical PharmaHealth Medical PharmaMilitary scienceNavigationPharmaceuticalRegulationSocial IssuesUKWomen's Health

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

06-05-2014

Confirming strong rumors over the past week or so, German pharma major Bayer confirmed it has agreed…

AdempasBayerLicensingMerck & CoMergers & AcquisitionsPharmaceuticalResearchRespiratory and Pulmonaryvericiguat

Bayer posts strong profits growth, with sales fueled by new drugs

Bayer posts strong profits growth, with sales fueled by new drugs

28-04-2014

German pharma and life sciences major Bayer saw its shares rise 4% to 99.60 euros by 9.30 this morning,…

BayerFinancialPharmaceutical

EMA recommends extending use of Bayer’s Nexavar

27-04-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

BayerEuropeNexavarOncologyPharmaceuticalRegulation

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

01-04-2014

German drug major Bayer presented new analyses from the pivotal ROCKET AF and EINSTEIN clinical trials…

BayerCardio-vascularJohnson & JohnsonPharmaceuticalResearchXarelto

Bayer’s Adempas gains EU clearance for two forms of PAH

Bayer’s Adempas gains EU clearance for two forms of PAH

31-03-2014

Following a previous positive opinion from the European Medicines Agency’s advisory committee, the…

AdempasBayerEuropePharmaceuticalRegulationRespiratory and Pulmonary

Bayer Healthcare to invest 100 million euros to expand capacity in China

Bayer Healthcare to invest 100 million euros to expand capacity in China

31-03-2014

The HealthCare division of Germany’s Bayer will invest around 100 million euros ($137.5 million) to…

Asia-PacificBayerChinaFinancialPharmaceuticalProduction

Transgene, Lee’s Pharma and SillaJen confirm clinical development plan for Pexa-Vec

27-03-2014

France’s Transgene, Hong Kong-based Lee’s Pharmaceutical and South Korea’s SillaJen have unveiled…

BayerLee's PharmaceuticalNexavarOncologyPexa-VecPharmaceuticalResearchSillaJenTransgene

UK’s NICE unable to give the go ahead to new prostate cancer drug Xofigo

24-03-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

BayerNorthern EuropeOncologyPharmaceuticalPricingRegulationUKXofigo

1 to 25 of 293 results

Back to top